Inhibrx Biosciences Inc Dossier
Qualitative Analysis
Business overview
Inhibrx Biosciences, Inc. (NASDAQ: INBX) is a clinical-stage biopharmaceutical company focused on developing engineered biologic therapeutics, primarily in oncology. The company emerged in May 2024 as an independent public entity following a corporate restructuring and the sale of legacy Inhibrx's rare disease program (INBRX-101) to Sanofi S.A. Inhibrx Biosciences retained the legacy oncology pipeline, which is built on its proprietary modular protein engineering platforms. Its lead clinical candidates are ozekibart (INBRX-109), a tetravalent death receptor 5 (DR5) agonist, and INBRX-106, a hexavalent OX40 agonist designed to optimize receptor activation and enhance T-cell co-stimulation.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the company's lead tetravalent DR5 agonist, ozekibart, through regulatory review for conventional chondrosarcoma and expanding clinical trials into colorectal cancer and Ewing sarcoma.
Expected impact: Establishment of the first approved systemic treatment for conventional chondrosarcoma and expansion into larger oncology markets.
Developing a hexavalent single-domain antibody-based therapeutic candidate targeting OX40 to treat metastatic solid tumors, with a primary focus on head and neck squamous cell carcinoma (HNSCC) in combination with pembrolizumab.
Expected impact: Demonstration of superior receptor clustering and T-cell activation over conventional bivalent therapies, validating the proprietary protein engineering platform.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides regional development and commercialization capabilities for ozekibart (INBRX-109) in Greater China, leveraging Transcenta's integrated biomanufacturing platform.
Terms: Transcenta holds exclusive rights to develop and commercialize ozekibart in mainland China, Hong Kong, Macau, and Taiwan under a licensing agreement executed through its subsidiary HJB.
Sanofi retained an 8% equity interest in Inhibrx Biosciences following the May 2024 spin-off transaction and provided $200 million in initial cash funding to capitalize the new independent entity.
Terms: Sanofi acquired legacy Inhibrx, Inc. for $30.00 per share in cash plus a CVR, while spinning off the non-INBRX-101 oncology assets into Inhibrx Biosciences with $200 million in cash and retaining an 8% stake.